Epidarex Capital appeared to be the VC, which was created in 2010. The company was established in North America in United States. The main office of represented VC is situated in the Bethesda.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Epidarex Capital, startups are often financed by Mercury Fund, Kei Aar, Imperial Innovations. The meaningful sponsors for the fund in investment in the same round are Scottish Investment Bank, venBio Partners, Imperial Innovations. In the next rounds fund is usually obtained by Pitch@Palace, Innovate UK, Imperial Innovations.
We also calculated 4 valuable employees in our database.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Clyde Biosciences, Sirakoss, Mironid. For fund there is no match between the location of its establishment and the land of its numerous investments - United Kingdom. Among the most successful fund investment fields, there are Medical, Health Diagnostics. The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.
The high activity for fund was in 2015. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. The higher amount of exits for fund were in 2017. The real fund results show that this VC is 40 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Epidarex Capital performs on 19 percentage points less the average number of lead investments. The usual things for fund are deals in the range of 10 - 50 millions dollars.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Aereco | - |
| Baohui Equity Investment | China, Fujian, Xiamen |
| C&I Capital | Beijing, Beijing, China |
| CKGSB Alumni Chuangchuang Fund | Beijing, Beijing, China |
| Convivialite Ventures | California, San Francisco, United States |
| Emkan Capital | Ar Riyad, Riyadh, Saudi Arabia |
| Firminvest | - |
| Goal Ventures | - |
| Huaxin Capital | China, Guangdong, Shenzhen |
| Indicator Ventures | New York, New York, United States |
| Lowe's Ventures | Mooresville, North Carolina, United States |
| M6 Ventures | California, La Jolla, United States |
| New York Times Digital | New York, New York, United States |
| Penn Venture Partners | Harrisburg, Pennsylvania, United States |
| ROOBO | Beijing, Beijing, China |
| Silver Chalice Ventures | Chicago, Illinois, United States |
| SMASHD Labs | California, Culver City, United States |
| The CDMN Soft-Landing Program | Canada, Kitchener, Ontario |
| The Kraft Group | Boxborough, Massachusetts, United States |
| Zhuhai Ailai Investment | China, Guangdong, Zhuhai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
IGEM Therapeutics | $17M | 09 Sep 2024 | London, England, United Kingdom | ||
Curve Therapeutics | $55M | 27 Feb 2024 | Southampton, Hampshire, United Kingdom | ||
Enterprise Therapeutics | $35M | 29 Jan 2024 | United Kingdom, England, United Kingdom | ||
Mironid | $42M | 13 Sep 2023 | United Kingdom, Scotland, United Kingdom | ||
MitraPlug | $20M | 18 Nov 2022 | Atlanta, Georgia, United States | ||
RapidPulse | $10M | 31 Aug 2022 | Miami, Florida, United States | ||
Transine Therapeutics | $6M | 31 May 2022 | Cambridge, England, United Kingdom | ||
Kynos Therapeutics | $8M | 07 Apr 2022 | - | ||
IGEM Therapeutics | $42M | 02 Mar 2022 | London, England, United Kingdom |
– Macomics Ltd has closed a follow-on financing of £4.24m from its 2020 Seed round, bringing the total amount raised to £7.44m.
– The additional investment brings in new investor Caribou Property Limited alongside existing investors Epidarex Capital, who led the round, and Scottish Enterprise.
– It will be used to accelerate the company’s growth, including expansion of the team.
– Macomics is developing precision medicines to modulate macrophages for the treatment of cancer.
– The company was co-founded in 2019 by Prof Jeffrey Pollard and Dr Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology.
– It is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages (‘TAMs’) towards the clinic.
– Theolytics, an Oxford, UK-based developer of a library of potential adenovirus product candidates and breakthrough bioselection systems, raised new funding from M Ventures.
– Funding was joined by Epidarex Capital and Taiho Ventures in an extension to the Series A financing.
– The expanded Series A funding will support the progress of internal programmes in ovarian cancer, and a second cancer indication in addition to further advancing the company’s technology platforms.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
IGEM Therapeutics | $17M | 09 Sep 2024 | London, England, United Kingdom | ||
Curve Therapeutics | $55M | 27 Feb 2024 | Southampton, Hampshire, United Kingdom | ||
Enterprise Therapeutics | $35M | 29 Jan 2024 | United Kingdom, England, United Kingdom | ||
Mironid | $42M | 13 Sep 2023 | United Kingdom, Scotland, United Kingdom | ||
MitraPlug | $20M | 18 Nov 2022 | Atlanta, Georgia, United States | ||
RapidPulse | $10M | 31 Aug 2022 | Miami, Florida, United States | ||
Transine Therapeutics | $6M | 31 May 2022 | Cambridge, England, United Kingdom | ||
Kynos Therapeutics | $8M | 07 Apr 2022 | - | ||
IGEM Therapeutics | $42M | 02 Mar 2022 | London, England, United Kingdom |
